... ' fierce attack on host cells. The work is described this week in the journal Nature. The enzyme, reverse transcriptase (RT), is already the target of two of the three major classes of existing anti- ...
... at one of the first class of HIV drugs approved by the U.S. Food and Drug Administration called nucleoside reverse transcriptase inhibitors (NRTIs) and a two-drug regimen that did not ...
... their RNA into DNA, using a special enzyme that they encode, called reverse transcriptase.
Once its RNA has been reverse-transcribed into DNA, the virion, having invaded a cell whose genetic ...
... increased, and though this leveled off after 2001, there followed an increasing use of nonnucleoside reverse transcriptase inhibitor-based HAART as the first-line treatment regimen and a substantial ...
... for treating HIV. The active ingredient in tenofovir belongs to a class of ARVs called nucleotide reverse transcriptase inhibitors (NRTIs), which act against HIV by targeting a key enzyme the virus ...
... Cancer Center.
The two essential components of human telomerase are telomerase RNA and telomerase reverse transcriptase. They are "recruited" to telomeres during what is called the "S phase" (for ...
... and during follow-up.
Changing Therapies
Virologic failure on an initial nonnucleoside reverse transcriptase inhibitor (NNRTI)- or ritonavir-boosted protease inhibitor-based regimen should be ...
... , to suppress the virus, researchers added either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor. They found no greater suppression in viral blood levels than seen before ...
... anti-HIV drugs, saquinavir, an HIV protease inhibitor (HPI) and zidovudine, a nucleoside reverse transcriptase inhibitor (NRTI), which are critical components of highly active antiretroviral therapy ( ...
... -dimensional structure of the enzyme's active region—the catalytic component called telomerase reverse transcriptase protein, or TERT.
The study revealed surprising features, including the fact that ...
... synthesis and biological evaluation of new compounds for tackling AIDS and HIV by inhibiting reverse transcriptase, the process by which this type of retrovirus virus hijacks the host cell's genetic ...
... in HHV-infected cells directly inhibits the HIV-1 reverse transcriptase (RT), thus preventing HIV from copying itself.
These results not only help to explain the response to ACV seen ...
... Africa.
Current World Health Organization guidelines recommend the use of a non-nucleoside reverse transcriptase inhibitor such as nevirapine or efavirenz in resource limited settings. Nearly 67 ...
... The nature of the binding site and mechanism of inhibition are analogous to those of the HIV-1 reverse transcriptase non-nucleoside inhibitors, which include four FDA-approved drugs for treating HIV- ...
... of Livin in fresh esophageal cancer tissues was detected by immunohistochemistry (IHC), Western blotting and reverse transcriptase-polymerase chain reaction (RT-PCR), VEGF by Its correlation Western ...
